The filing is a routine procedural update with no change to deal terms or board recommendation. Monitor the November 16 tender expiration and any competing bids or regulatory developments before that date.
Price Chart
Executive Summary
Pacira BioSciences filed Amendment No. 1 to its Schedule 14D-9, adding an Employee FAQ as an exhibit. The FAQ details the treatment of stock options, RSUs, restricted cash awards, and the ESPP in connection with Viatris's pending $36.50/share cash tender offer. The board continues to recommend the offer, and the transaction is expected to close on or around November 17, 2026.
Key Facts
- Amendment No. 1 to Schedule 14D-9 filed on November 3, 2026, adding Exhibit (a)(5)(K) (Employee FAQ).
- Viatris tender offer at $36.50 per share in cash, commenced October 30, 2026.
- Offer expires November 16, 2026; transaction expected to close on or around November 17, 2026.
- Stock options with exercise price below $36.50 will be canceled and converted to cash for the spread.
- Stock options with exercise price at or above $36.50 will be canceled for no consideration.
- RSUs (vested or unvested) will be canceled and converted to cash at $36.50 per share.
- Restricted cash awards will be paid out at closing.
- ESPP will terminate at closing; accumulated contributions used to buy shares on November 4, 2026, then converted to cash at $36.50.
- Vested stock option exercise deadline is November 6, 2026 at 4:00 p.m. Eastern time.
Financial Impact
No new financial figures; offer price remains $36.50 per share, aggregate equity value $1.65 billion per prior filings.
Risk Factors
- Risk that minimum tender condition (majority of outstanding shares) is not met.
- Risk that a competing offer emerges before the November 16 expiration.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 14D-9/A Filing (Primary) | 0001140361-26-041805 |
| Document: ny20084560x2_sc14d9a.htm | 0001140361-26-041805 |
| Document: 0001140361-26-041805-index-headers.html | 0001140361-26-041805 |
| Document: 0001140361-26-041805-index.html | 0001140361-26-041805 |
| Document: 0001140361-26-041805.txt | 0001140361-26-041805 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 3, 2026 1d ago | SC 14D-9/A | $36.41 | awaiting T+60 | awaiting T+60 | $36.40 (−0.03%) |
Oct 30, 2026 5d ago | SC 13G/A | $36.39 | awaiting T+60 | awaiting T+60 | $36.40 (+0.03%) |
Oct 30, 2026 5d ago | SC 14D-9 | $36.39 | awaiting T+60 | awaiting T+60 | $36.40 (+0.03%) |
Oct 30, 2026 5d ago | SC TO-T | $36.39 | awaiting T+60 | awaiting T+60 | $36.40 (+0.03%) |
Oct 13, 2026 22d ago | SC 13D/A | $36.40 | awaiting T+60 | awaiting T+60 | $36.40 (−0.00%) |
Oct 8, 2026 27d ago | SC TO-C | $36.31 | awaiting T+60 | awaiting T+60 | $36.40 (+0.25%) |
Oct 8, 2026 27d ago | 144 | $36.39 | awaiting T+60 | awaiting T+60 | $36.40 (+0.03%) |
Oct 8, 2026 27d ago | 8-K | $36.39 | awaiting T+60 | awaiting T+60 | $36.40 (+0.03%) |
Oct 8, 2026 27d ago | SC TO-C | $36.39 | awaiting T+60 | awaiting T+60 | $36.40 (+0.03%) |
Aug 6, 2026 12w ago | Press Release | $25.58 $36.39 | ▲ +42.26% | ▲ +43.93% | $36.40 (+42.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers